Recursion Pharmaceuticals (NASDAQ:RXRX) Director Namandje Bumpus Sells 3,963 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Namandje Bumpus sold 3,963 shares of the firm’s stock in a transaction that occurred on Thursday, June 18th. The stock was sold at an average price of $3.18, for a total transaction of $12,602.34. Following the transaction, the director directly owned 127,632 shares of the company’s stock, valued at $405,869.76. This represents a 3.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Namandje Bumpus also recently made the following trade(s):

• On Wednesday, June 3rd, Namandje Bumpus sold 4,386 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $3.54, for a total transaction of $15,526.44.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded down $0.05 during trading hours on Monday, hitting $3.18. The company’s stock had a trading volume of 14,388,337 shares, compared to its average volume of 17,503,381. The company has a 50 day moving average of $3.32 and a 200 day moving average of $3.74. The stock has a market cap of $1.69 billion, a PE ratio of -2.65 and a beta of 1.04. The company has a current ratio of 5.47, a quick ratio of 5.47 and a debt-to-equity ratio of 0.01. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.08. Recursion Pharmaceuticals had a negative net margin of 842.95% and a negative return on equity of 54.33%. The firm had revenue of $6.47 million during the quarter, compared to analysts’ expectations of $15.78 million. During the same quarter last year, the company posted ($0.50) earnings per share. The firm’s revenue was down 56.8% compared to the same quarter last year. On average, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE grew its position in shares of Recursion Pharmaceuticals by 18.2% during the 1st quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after acquiring an additional 384,486 shares during the period. Janus Henderson Group PLC raised its holdings in Recursion Pharmaceuticals by 59.4% in the 1st quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock worth $675,000 after purchasing an additional 82,100 shares during the period. California State Teachers Retirement System boosted its position in Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock worth $1,764,000 after purchasing an additional 224,332 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Recursion Pharmaceuticals by 7.3% during the first quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock worth $675,000 after purchasing an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC acquired a new stake in Recursion Pharmaceuticals in the first quarter valued at approximately $236,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on RXRX. Morgan Stanley lifted their price objective on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the company an “equal weight” rating in a research note on Thursday, May 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Thursday, May 7th. Bank of America reduced their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a “neutral” rating for the company in a research report on Wednesday, February 25th. Wall Street Zen downgraded Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Recursion Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $8.10.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.